vs
南玻集团（CSGS）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是Prestige Consumer Healthcare Inc.的1.1倍（$323.1M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 2.2%，领先14.3%），南玻集团同比增速更快（2.0% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $55.8M），过去两年南玻集团的营收复合增速更高（4.6% vs 1.2%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
CSGS vs PBH — 直观对比
营收规模更大
CSGS
是对方的1.1倍
$283.4M
营收增速更快
CSGS
高出4.4%
-2.4%
净利率更高
PBH
高出14.3%
2.2%
自由现金流更多
PBH
多$19.5M
$55.8M
两年增速更快
CSGS
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $283.4M |
| 净利润 | $7.0M | $46.7M |
| 毛利率 | 50.0% | 55.5% |
| 营业利润率 | 9.0% | 29.1% |
| 净利率 | 2.2% | 16.5% |
| 营收同比 | 2.0% | -2.4% |
| 净利润同比 | -79.7% | -23.5% |
| 每股收益（稀释后） | $0.24 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSPBH
| Q4 25 | $323.1M | $283.4M | ||
| Q3 25 | $303.6M | $274.1M | ||
| Q2 25 | $297.1M | $249.5M | ||
| Q1 25 | $299.5M | $296.5M | ||
| Q4 24 | $316.7M | $290.3M | ||
| Q3 24 | $295.1M | $283.8M | ||
| Q2 24 | $290.3M | $267.1M | ||
| Q1 24 | $295.1M | $277.0M |
净利润CSGSPBH
| Q4 25 | $7.0M | $46.7M | ||
| Q3 25 | $20.5M | $42.2M | ||
| Q2 25 | $12.3M | $47.5M | ||
| Q1 25 | $16.1M | $50.1M | ||
| Q4 24 | $34.5M | $61.0M | ||
| Q3 24 | $19.1M | $54.4M | ||
| Q2 24 | $13.8M | $49.1M | ||
| Q1 24 | $19.5M | $49.5M |
毛利率CSGSPBH
| Q4 25 | 50.0% | 55.5% | ||
| Q3 25 | 48.1% | 55.3% | ||
| Q2 25 | 49.5% | 56.2% | ||
| Q1 25 | 48.4% | 57.3% | ||
| Q4 24 | 51.3% | 55.5% | ||
| Q3 24 | 49.4% | 55.5% | ||
| Q2 24 | 47.3% | 54.7% | ||
| Q1 24 | 46.5% | 54.8% |
营业利润率CSGSPBH
| Q4 25 | 9.0% | 29.1% | ||
| Q3 25 | 10.0% | 29.1% | ||
| Q2 25 | 10.0% | 28.8% | ||
| Q1 25 | 9.8% | 29.8% | ||
| Q4 24 | 13.4% | 31.7% | ||
| Q3 24 | 10.8% | 29.7% | ||
| Q2 24 | 8.8% | 27.0% | ||
| Q1 24 | 10.8% | 29.7% |
净利率CSGSPBH
| Q4 25 | 2.2% | 16.5% | ||
| Q3 25 | 6.7% | 15.4% | ||
| Q2 25 | 4.1% | 19.0% | ||
| Q1 25 | 5.4% | 16.9% | ||
| Q4 24 | 10.9% | 21.0% | ||
| Q3 24 | 6.5% | 19.2% | ||
| Q2 24 | 4.8% | 18.4% | ||
| Q1 24 | 6.6% | 17.9% |
每股收益（稀释后）CSGSPBH
| Q4 25 | $0.24 | $0.97 | ||
| Q3 25 | $0.73 | $0.86 | ||
| Q2 25 | $0.44 | $0.95 | ||
| Q1 25 | $0.57 | $1.00 | ||
| Q4 24 | $1.20 | $1.22 | ||
| Q3 24 | $0.67 | $1.09 | ||
| Q2 24 | $0.48 | $0.98 | ||
| Q1 24 | $0.68 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $62.4M |
| 总债务越低越好 | $539.5M | $1.0B |
| 股东权益账面价值 | $283.7M | $1.8B |
| 总资产 | $1.5B | $3.5B |
| 负债/权益比越低杠杆越低 | 1.90× | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资CSGSPBH
| Q4 25 | $180.0M | $62.4M | ||
| Q3 25 | $158.4M | $119.1M | ||
| Q2 25 | $145.9M | $139.5M | ||
| Q1 25 | $136.0M | $97.9M | ||
| Q4 24 | $161.8M | $50.9M | ||
| Q3 24 | $118.4M | $51.5M | ||
| Q2 24 | $110.4M | $34.3M | ||
| Q1 24 | $120.8M | $46.5M |
总债务CSGSPBH
| Q4 25 | $539.5M | $1.0B | ||
| Q3 25 | $538.6M | $993.1M | ||
| Q2 25 | $537.8M | $992.7M | ||
| Q1 25 | $537.6M | $992.4M | ||
| Q4 24 | $538.5M | $992.0M | ||
| Q3 24 | $539.5M | $1.1B | ||
| Q2 24 | $540.5M | $1.1B | ||
| Q1 24 | $541.5M | $1.1B |
股东权益CSGSPBH
| Q4 25 | $283.7M | $1.8B | ||
| Q3 25 | $289.5M | $1.8B | ||
| Q2 25 | $290.7M | $1.9B | ||
| Q1 25 | $283.1M | $1.8B | ||
| Q4 24 | $282.6M | $1.8B | ||
| Q3 24 | $288.4M | $1.7B | ||
| Q2 24 | $273.3M | $1.7B | ||
| Q1 24 | $269.3M | $1.7B |
总资产CSGSPBH
| Q4 25 | $1.5B | $3.5B | ||
| Q3 25 | $1.5B | $3.4B | ||
| Q2 25 | $1.4B | $3.4B | ||
| Q1 25 | $1.4B | $3.4B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.4B | $3.3B | ||
| Q2 24 | $1.4B | $3.3B | ||
| Q1 24 | $1.3B | $3.3B |
负债/权益比CSGSPBH
| Q4 25 | 1.90× | 0.56× | ||
| Q3 25 | 1.86× | 0.54× | ||
| Q2 25 | 1.85× | 0.54× | ||
| Q1 25 | 1.90× | 0.54× | ||
| Q4 24 | 1.91× | 0.55× | ||
| Q3 24 | 1.87× | 0.61× | ||
| Q2 24 | 1.98× | 0.65× | ||
| Q1 24 | 2.01× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $75.3M |
| 自由现金流率自由现金流/营收 | 17.3% | 26.6% |
| 资本支出强度资本支出/营收 | 1.1% | 1.1% |
| 现金转化率经营现金流/净利润 | 8.46× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $141.4M | $267.2M |
8季度趋势，按日历期对齐
经营现金流CSGSPBH
| Q4 25 | $59.2M | $78.3M | ||
| Q3 25 | $47.9M | $57.5M | ||
| Q2 25 | $37.3M | $79.0M | ||
| Q1 25 | $11.5M | $61.8M | ||
| Q4 24 | $82.5M | $65.1M | ||
| Q3 24 | $39.5M | $69.8M | ||
| Q2 24 | $43.1M | $54.8M | ||
| Q1 24 | $-29.4M | $66.9M |
自由现金流CSGSPBH
| Q4 25 | $55.8M | $75.3M | ||
| Q3 25 | $43.9M | $55.4M | ||
| Q2 25 | $34.6M | $78.2M | ||
| Q1 25 | $7.1M | $58.4M | ||
| Q4 24 | $76.6M | $63.5M | ||
| Q3 24 | $32.0M | $67.8M | ||
| Q2 24 | $38.8M | $53.6M | ||
| Q1 24 | $-34.1M | $63.8M |
自由现金流率CSGSPBH
| Q4 25 | 17.3% | 26.6% | ||
| Q3 25 | 14.5% | 20.2% | ||
| Q2 25 | 11.6% | 31.3% | ||
| Q1 25 | 2.4% | 19.7% | ||
| Q4 24 | 24.2% | 21.9% | ||
| Q3 24 | 10.8% | 23.9% | ||
| Q2 24 | 13.4% | 20.1% | ||
| Q1 24 | -11.6% | 23.0% |
资本支出强度CSGSPBH
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 0.9% | 0.3% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 1.9% | 0.5% | ||
| Q3 24 | 2.5% | 0.7% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 1.6% | 1.1% |
现金转化率CSGSPBH
| Q4 25 | 8.46× | 1.68× | ||
| Q3 25 | 2.34× | 1.36× | ||
| Q2 25 | 3.04× | 1.66× | ||
| Q1 25 | 0.71× | 1.23× | ||
| Q4 24 | 2.39× | 1.07× | ||
| Q3 24 | 2.07× | 1.28× | ||
| Q2 24 | 3.12× | 1.12× | ||
| Q1 24 | -1.51× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
